Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
December 15, 2025 10:24 AM EST
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $942.00 price target on argenx SE (NASDAQ: ARGX)
The analyst comments "Argenx (ARGX) announced the phase 3 UplighTED studies evaluating efgartigimod in thyroid eye disease (TED) will be discontinued following a pre-specified futility analysis. Management highlighted... More
December 15, 2025 6:56 AM EST
argenx SE (Euronext & Nasdaq: ARGX) announced it will discontinue its Phase 3 UplighTED studies evaluating efgartigimod subcutaneous in adults with moderate to severe thyroid eye disease.
The decision follows a recommendation from an Independent Data Monitoring Committee to stop the trials for futility after reviewing data from a pre-specified interim... More
December 11, 2025 6:54 AM EST
Stifel analyst Alex Thompson raised the price target on argenx SE (NASDAQ: ARGX) to $1,248.00 (from $1,028.00) while maintaining a Buy rating.
The analyst commented, "Vyvgart continues to dominate the MG market as the #1 prescribed biologic in the space while growing faster... More
December 11, 2025 6:25 AM EST
Wells Fargo analyst Yanan Zhu raised the price target on argenx SE (NASDAQ: ARGX) to $1,316.00 (from $1,095.00) while maintaining a Overweight rating.... More
